NovoCure Limited (NVCR Quick QuoteNVCR - Free Report) was a big mover last session, as the company saw its shares rise around 6% on the day. Shares gained after the company reported positive data from a pivotal phase III trial on Optune, in combination with temozolomide, for the treatment of newly diagnosed glioblastoma. The news led to far more shares changing hands than in a normal session resulting in solid volume. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $7.68 to $8.51 in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

NovoCure currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

A better-ranked stock in the same industry is The Advisory Board Company , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here .

Is NVCR going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>